Establishment of a new human myeloma cell line (U-2030) and selection of a hat-sensitive subline.
We have established a new human myeloma cell line from the pleural effusion of a patient with an IgA lambda myeloma, using special tissue culture conditions and selection procedures to prevent the outgrowth of contaminating Epstein-Barr virus (EBV)-carrying normal B-lymphoblastoid cells present in the explant. The myeloma cell line, U-2030, is aneuploid and EBNA-negative and has morphological features, reactivity with cytochemical markers and cell-surface antigen expression typical of plasmablasts. The cell line thus appears to be representative of the malignant clone in vivo. However, functionally the line is a non-Ig-producer and must therefore be derived from a non-secretory variant cell present within the highly aneuploid myeloma cell clone in vivo. The U-2030 differs from previously established human myeloma cell lines in that it has a comparatively high growth rate, is clonable and can be made HAT-sensitive relatively easily. This, together with the facts that it is a non-Ig-producer and mycoplasma-free, suggests that the 6-thioguanine-resistant, HAT-sensitive subline, U-2030 TG, derived from this cell line may be used as a malignant fusion partner for the production of human-human hybridomas. An EBV-carrying lymphoblastoid cell line (U-2031) was also established. This line was diploid and had all the phenotypic properties of lymphoblastoid lines established from normal individuals.
D000630:Aminopterin; D000954:Antigens, Surface / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols; D002460:Cell Line; D004351:Drug Resistance; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines; D007136:Immunoglobulins / Q000096:biosynthesis; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D013936:Thymidine
D000954:Antigens, Surface; D007042:Hypoxanthines; D007136:Immunoglobulins; D019271:Hypoxanthine; D000630:Aminopterin; D013936:Thymidine